GlaxoSmithKline‘s (NYSE:GSK) interest in tiny neural implants is stronger than ever, even amid declining earnings and flopped drug candidates that have turned CEO Andrew Witty into a lame duck who will step aside in 2017. Despite the turmoil, the British pharma giant is investing $50 million in so-called bioelectronics via Action Potential Ventures, aiming to fund companies […]
(Reuters) – Johnson & Johnson (NYSE:JNJ) is seeking to sell its manufacturer of active pharmaceutical ingredients, Noramco, in a move that could value the division at as much as $800 million, according to people familiar with the matter. Noramco is attracting interest primarily from buyout firms, the people said this week. The unit has annual […]
Before Stephen Ubl departed for a job as the chief lobbyist for the pharmaceutical industry, medtech’s main man in Washington, D.C., sat down with MassDevice.com publisher Brian Johnson to reflect on his time at AdvaMed. Ubl worked 16 years at the Advanced Medical Technology Assn., spending the last 10 years as president & CEO, raising the medical device industry’s national […]
Having been at the flag-raising ceremony for Hospira when it spun out of Abbott back in 2004, the news of Pfizer’s acquisition was a bit emotional for me. I didn’t cry or anything, but I did feel a little sad, and a little proud, and maybe a little hopeful at the end of the day.
By Tom Ulrich
by Charles Ornstein, ProPublica
The federal government has a word for physicians who don’t have financial relationships with pharmaceutical and medical device manufacturers: "Error."